2. Search Result
Search Result
Results for "

Myocardial ischemia

" in MedChemExpress (MCE) Product Catalog:

109

Inhibitors & Agonists

1

Screening Libraries

1

Fluorescent Dye

1

Biochemical Assay Reagents

11

Peptides

2

Inhibitory Antibodies

17

Natural
Products

6

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W009512
    CVT-2738

    RS-94287

    		 Drug Metabolite Cardiovascular Disease
    CVT-2738 is an orally active metabolite of Ranolazine (HY-B0280). CVT-2738 has a protective effect against Isoprenaline (HY-108353)-induced myocardial ischemia in mice. CVT-2738 can be used in myocardial ischemia research .
    CVT-2738
  • HY-106262B
    Delcasertib hydrochloride
    3 Publications Verification

    KAI-9803 hydrochloride; BMS-875944 hydrochloride

    		 PKC Cardiovascular Disease Inflammation/Immunology
    Delcasertib (KAI-9803) hydrochloride is a potent and selective δ-protein kinase C (δPKC) inhibitor. Delcasertib (KAI-9803) hydrochloride could ameliorate injury associated with ischemia and reperfusion in animal models of acute myocardial infarction (MI) .
    Delcasertib hydrochloride
  • HY-W011082
    NLRP3-IN-2

    		NOD-like Receptor (NLR) Cardiovascular Disease
    NLRP3-IN-2, an intermediate substrate in the synthesis of glyburide, inhibits the formation of the NLRP3 inflammasome in cardiomyocytes and limits the infarct size following myocardial ischemia/reperfusion in the mouse, without affecting glucose metabolism .
    NLRP3-IN-2
  • HY-10915
    LUF6096

    		Adenosine Receptor Cardiovascular Disease
    LUF6096, a potent allosteric enhancer of the adenosine A3 receptor, is able to allosterically enhance agonist binding. LUF6096 shows low orthosteric affinity for any of the adenosine receptors. LUF6096 shows protective effects in myocardial ischemia/reperfusion injury .
    LUF6096
  • HY-W009512R
    CVT-2738 (Standard)

    RS-94287 (Standard)

    		 Drug Metabolite Reference Standards Cardiovascular Disease
    CVT-2738 (Standard) is the analytical standard of CVT-2738. This product is intended for research and analytical applications. CVT-2738 is an orally active metabolite of Ranolazine (HY-B0280). CVT-2738 has a protective effect against isoprenaline (HY-108353)-induced myocardial ischemia in mice. CVT-2738 can be used in myocardial ischemia research .
    CVT-2738 (Standard)
  • HY-111084
    UK 52831

    		Calcium Channel Cardiovascular Disease Inflammation/Immunology
    UK 52831 is a long acting dihydropyridine calcium channel antagonist. UK 52831 can be used for cardiovascular disease (such as hypertension and myocardial ischemia) and anti-inflammatory research .
    UK 52831
  • HY-W714710
    Teopranitol

    KC-046

    		 Prostaglandin Receptor Cardiovascular Disease
    Teopranitol (KC-046), a coronary vasodilator with a rather selective venous dilatation, is used for the study of the acute myocardial ischemia .
    Teopranitol
  • HY-149736
    ATP Synthesis-IN-3

    		PKA ATP Synthase Cardiovascular Disease
    ATP Synthesis-IN-3 (compound 31) is an ATP hydrolysis inhibitor with protective effects during myocardial ischemia. ATP Synthesis-IN-3 can increase the ATP content of ischemic cardiomyocytes, increase the phosphorylation of PKA and phospholamban, and inhibit ischemia-induced apoptosis .
    ATP Synthesis-IN-3
  • HY-114671
    Taprostene

    CG-4203

    		 Prostaglandin Receptor Cardiovascular Disease
    Taprostene (CG-4203) is a synthetic, chemically stable analogue of Prostacyclin (PGI2). Taprostene exhibits endothelium and myocardial protecting actions after acute myocardial ischemia and reperfusion in cats. Taprostene enhances cytoprotective actions, while minimizing unwanted hemodynamic effects .
    Taprostene
  • HY-175640
    Troponin-IN-1

    		Pyroptosis Reactive Oxygen Species (ROS) Interleukin Related Caspase Cardiovascular Disease
    Troponin-IN-1 is a troponin inhibitor. Troponin-IN-1 protects OGD/R-injured H9c2 cardiomyocytes by reducing LDH leakage, pyroptosis and ROS accumulation. Troponin-IN-1 inhibits NO production and IL-1β/TNF-α/IL-18 release in LPS (HY-D1056)-induced RAW264.7 cells. Troponin-IN-1 acts via caspase-1/GSDMD/IL-18 pathway. Troponin-IN-1 reduces myocardial infarct size in LAD-induced myocardial ischemia/reperfusion (MI/R) male rats. Troponin-IN-1 can be used for the study of myocardial ischemia/reperfusion (MI/R) injury .
    Troponin-IN-1
  • HY-164304
    INF 195

    		Pyroptosis Interleukin Related NOD-like Receptor (NLR) Cardiovascular Disease Inflammation/Immunology
    INF 195 is an NLRP3 inhibitor. INF 195 can inhibit NLRP3 driven macrophage pyroptosis and IL-1β release, with an EC50 value of 0.15 μM. INF 195 can reduce the infarct size of isolated mouse hearts at low doses, effectively preventing myocardial ischemia/reperfusion injury .
    INF 195
  • HY-121726
    3HOI-BA-01

    		mTOR Autophagy Cardiovascular Disease
    3HOI-BA-01 is amTORinhibitor.3HOI-BA-01reduces infarct size and inducedautophagyin a murine myocardial ischemia/reperfusion injury model .
    3HOI-BA-01
  • HY-139397
    TJ-M2010-5
    20+ Cited Publications

    		 MyD88 Cardiovascular Disease
    TJ-M2010-5 is a MyD88 inhibitor that binds to the TIR domain of MyD88 to interfere with its homodimerization, and the TLR/MyD88 signal pathway . TJ-M2010-5 can be used for the research of myocardial ischemia/reperfusion injury (MIRI) .
    TJ-M2010-5
  • HY-110315
    Ischemin sodium

    		Apoptosis MDM-2/p53 Epigenetic Reader Domain Cardiovascular Disease
    Ischemin sodium is a CBP bromodomain inhibitor that inhibits p53 interaction with CBP and transcriptional activity in cells. Ischemin sodium salt inhibits p53-induced p21 activation with an IC50 value of 5 µM. Ischemin sodium salt also prevents apoptosis in ischemic cardiomyocytes. Ischemin sodium salt can be used in the study of cardiovascular diseases (such as myocardial ischemia) .
    Ischemin sodium
  • HY-177249
    Salvianolic acid A derivative-1

    		Arp2/3 Complex Cardiovascular Disease
    Salvianolic acid A derivative-1 (Compound SAA-30) is a orally active derivative of Salvianolic acid A (HY-N0318). Salvianolic acid A derivative-1 binds to transgelin with a KD of 2.39 μM. Salvianolic acid A derivative-1 promotes cell contractions by facilitating the aggregation of actin. Salvianolic acid A derivative-1 can be used for prevention of myocardial ischemia or other diseases associated with IR tissue injuries .
    Salvianolic acid A derivative-1
  • HY-106865
    Mivazerol

    		Dopamine Receptor Adrenergic Receptor Cardiovascular Disease
    Mivazerol is a selective α2-adrenoceptor agonist. Mivazerol has an anti-ischemic activity. Mivazerol decreases the spontaneous release of serotonin (5-HT) and significantly inhibits the immobilization stress-induced enhancement of norepinephrine (NE), dopamine (DA) and dihydroxyphenylacetic acid (DOPAC). Mivazerol can be used for myocardial ischemia research .
    Mivazerol
  • HY-105218A
    Ifetroban sodium
    1 Publications Verification

    BMS-180291 sodium

    		 Prostaglandin Receptor Cardiovascular Disease Endocrinology Cancer
    Ifetroban (BMS-180291) sodium is an orally active antagonist of thromboxane A2 (TXA2) or prostaglandin H2 (PGH2) receptor. Ifetroban sodium shows antiplatelet activity, and inhibits tumor cell migration without affecting cell proliferation. Ifetroban sodium can be used for myocardial ischemia, hypertension, stroke, thrombosis, cardiomyopathy research .
    Ifetroban sodium
  • HY-105218
    Ifetroban
    1 Publications Verification

    BMS-180291

    		 Prostaglandin Receptor Cardiovascular Disease Endocrinology Cancer
    Ifetroban (BMS-180291) is an orally active antagonist of thromboxane A2 (TXA2) or prostaglandin H2 (PGH2) receptor. Ifetroban shows antiplatelet activity, and inhibits tumor cell migration without affecting cell proliferation. Ifetroban can be used for myocardial ischemia, hypertension, stroke, thrombosis, cardiomyopathy research .
    Ifetroban
  • HY-P3565
    Sarafotoxin S6d

    STX-b

    		 Calcium Channel Cardiovascular Disease
    Sarafotoxin S6d (STX-b) is a polypeptide toxin isolated from the venom of the Israeli sand boa constrictor. Sarafotoxin S6d induces multiple electrocardiogram (ECG) changes including myocardial ischemia and hyperkalemia. Sarafotoxin S6d induces strong extracellular calcium-dependent vasoconstriction in rat aorta and exhibits positive inotropic effects in rat atria. Sarafotoxin S6d can be used in the study of cardiovascular diseases .
    Sarafotoxin S6d
  • HY-103171
    BAY 60-6583
    5+ Cited Publications

    		 Adenosine Receptor Cardiovascular Disease Inflammation/Immunology
    BAY 60-6583 is a potent and high-affinity agonist of adenosine A2B receptor (EC50=3 nM) over A1, A2A, and A3 receptors. BAY 60-6583 binds to mouse, rabbit, and dog A2BAR with Ki values of 750 nM, 340 nM and 330 nM, respectively. BAY 60-6583 has a cardioprotective effect in a myocardial ischemia model .
    BAY 60-6583
  • HY-103171R
    BAY 60-6583 (Standard)

    		Reference Standards Adenosine Receptor Cardiovascular Disease Inflammation/Immunology
    BAY 60-6583 (Standard) is the analytical standard of BAY 60-6583. This product is intended for research and analytical applications. BAY 60-6583 is a potent and high-affinity agonist of adenosine A2B receptor (EC50?= 3 nM) over A1, A2A, and A3 receptors. BAY 60-6583 binds to mouse, rabbit, and dog A2BAR with Ki values of 750 nM, 340 nM and 330 nM, respectively. BAY 60-6583 has a cardioprotective effect in a myocardial ischemia model .
    BAY 60-6583 (Standard)
  • HY-122525B
    Sabiporide mesylate

    BIIB 722 mesylate

    		 Endogenous Metabolite Cardiovascular Disease
    Sabiporide (BIIB 722 mesylate) mesylate is a selective inhibitor of sodium-hydrogen exchange, known for its cardioprotective properties, making it a valuable tool for investigating myocardial ischemia and myocardial infarction.
    Sabiporide mesylate
  • HY-176716
    ALDH2 activator 1

    		Aldehyde Dehydrogenase (ALDH) Cardiovascular Disease
    ALDH2 activator 1 (Compound Z17) is an allosteric aldehyde dehydrogenase 2 (ALDH2) agonist. ALDH2 activator 1 enhances cardiac function and reduces myocardial necrosis in a mouse model of myocardial ischemia-reperfusion. ALDH2 activator 1 is promising for research of cardiovascular diseases such as myocardial infarction (MI) .
    ALDH2 activator 1
  • HY-122005
    AVE-9488

    		NO Synthase Inflammation/Immunology
    AVE-9488 is an eNOS enhancer with the activity of protecting the heart from ischemia-reperfusion injury. AVE-9488 can upregulate eNOS expression, increase NO production, reduce myocardial ischemia-reperfusion injury, and reduce the level of reactive oxygen species .
    AVE-9488
  • HY-76144
    4-Aminobenzothioamide

    4-Aminothiobenzamide

    		 Biochemical Assay Reagents Cardiovascular Disease
    3-Aminobenzothioamide is a small H2S donor. 3-Aminobenzothioamide has the potential for the research of myocardial ischemia-reperfusion injury .
    4-Aminobenzothioamide
  • HY-N2638
    Ilexsaponin A

    		Apoptosis Cardiovascular Disease
    Ilexsaponin A, isolated from the root of Ilex pubescens, attenuates ischemia-reperfusion-induced myocardial injury through anti-apoptotic pathway. Ilexsaponin A can reduce myocardial infarct size, lower the serum levels of LDH, AST and CK-MB, increase cellular viability and inhibit apoptosis in hypoxia/reoxygenation cardiomyocytes .
    Ilexsaponin A
  • HY-136744
    Caspase-9 Inhibitor III

    Ac-LEHD-cmk

    		 Caspase Cardiovascular Disease
    Caspase-9 Inhibitor III (Ac-LEHD-cmk) is a caspase-9 inhibitor. Caspase-9 Inhibitor III exhibits protective effects on ischemia-reperfusion-induced myocardial injury .
    Caspase-9 Inhibitor III
  • HY-E70008
    Lumbokinase

    		Sirtuin Inflammation/Immunology
    Lumbokinase attenuates myocardial ischemia-reperfusion (I-R) injury through the activation of Sirt1 signaling, and thus enhances autophagic flux and reduces I-R-induced oxidative damage, inflammation and apoptosis .
    Lumbokinase
  • HY-125144
    BIIB 513

    		Na+/H+ Exchanger (NHE) Cardiovascular Disease
    BIIB 513 is an inhibitor of NHE 1 that protects against myocardial ischemia. BIIB 513 inhibits acid load recovery with an IC50 of 27 nmol/L in cells expressing wild-type NHE 1 under acute acid load .
    BIIB 513
  • HY-N15744
    Anti-Heart Failure Agent 3

    		NO Synthase Cardiovascular Disease
    Anti-Heart Failure Agent 3 (Compound 2) is an anti-heart failure agent with anti-inflammatory activity found in processed Cornus officinalis. Anti-Heart Failure Agent 3 inhibits NO release in LPS-induced RAW264.7 cells. Anti-Heart Failure Agent 3 alleviates myocardial ischemia-reperfusion injury, reduces myocardial infarction size, and improves myocardial histopathological changes. Anti-Heart Failure Agent 3 is promising for research of heart failure .
    Anti-Heart Failure Agent 3
  • HY-N15743
    Anti-Heart Failure Agent 2

    		NO Synthase Cardiovascular Disease
    Anti-Heart Failure Agent 2 (Compound 1) is an anti-heart failure agent with anti-inflammatory activity found in processed Cornus officinalis. Anti-Heart Failure Agent 2 inhibits NO release in LPS-induced RAW264.7 cells. Anti-Heart Failure Agent 2 alleviates myocardial ischemia-reperfusion injury, reduces myocardial infarction size, and improves myocardial histopathological changes. Anti-Heart Failure Agent 2 is promising for research of heart failure .
    Anti-Heart Failure Agent 2
  • HY-N15745
    Anti-Heart Failure Agent 4

    		NO Synthase Cardiovascular Disease
    Anti-Heart Failure Agent 4 (Compound 3) is an anti-heart failure agent with anti-inflammatory activity found in processed Cornus officinalis. Anti-Heart Failure Agent 4 inhibits NO release in LPS-induced RAW264.7 cells. Anti-Heart Failure Agent 4 alleviates myocardial ischemia-reperfusion injury, reduces myocardial infarction size, and improves myocardial histopathological changes. Anti-Heart Failure Agent 4 is promising for research of heart failure .
    Anti-Heart Failure Agent 4
  • HY-103641AR
    (2S)-Octyl-α-hydroxyglutarate (Standard)

    (2S)-Octyl-2-HG (Standard)

    		 Drug Derivative Reference Standards Others Cancer
    CVT-2738 (Standard) is the analytical standard of CVT-2738. This product is intended for research and analytical applications. CVT-2738 is a Ranolazine (HY-B0280) Metabolite, and shows anti-myocardial ischemia activities .
    (2S)-Octyl-α-hydroxyglutarate (Standard)
  • HY-W009512S1
    CVT-2738-d6

    RS-94287-d6

    		 Isotope-Labeled Compounds Others
    N-(2,6-Dimethylphenyl)-2-(piperazin-1-yl)acetamide-d6 (N-[(2-chlorophenyl)carbamoyl]phenylalanine-d6) is deuterium-labeled CVT-2738 (HY-W009512). CVT-2738 is an orally active metabolite of Ranolazine (HY-B0280). CVT-2738 has a protective effect against isoprenaline (HY-108353)-induced myocardial ischemia in mice. CVT-2738 can be used in myocardial ischemia research .
    CVT-2738-d6
  • HY-17369B
    Tirofiban
    4 Publications Verification

    L700462; MK383

    		 Integrin Cardiovascular Disease
    Tirofiban (L700462) is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area .
    Tirofiban
  • HY-N2638R
    Ilexsaponin A (Standard)

    		Reference Standards Apoptosis Cardiovascular Disease
    Ilexsaponin A (Standard) is the analytical standard of Ilexsaponin A. This product is intended for research and analytical applications. Ilexsaponin A, isolated from the root of Ilex pubescens, attenuates ischemia-reperfusion-induced myocardial injury through anti-apoptotic pathway. Ilexsaponin A can reduce myocardial infarct size, lower the serum levels of LDH, AST and CK-MB, increase cellular viability and inhibit apoptosis in hypoxia/reoxygenation cardiomyocytes .
    Ilexsaponin A (Standard)
  • HY-17369A
    Tirofiban hydrochloride

    L700462 hydrochloride; MK383 hydrochloride

    		 Integrin Cardiovascular Disease
    Tirofiban (L700462) hydrochloride is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban hydrochloride induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban hydrochloride can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area .
    Tirofiban hydrochloride
  • HY-17369
    Tirofiban hydrochloride monohydrate
    4 Publications Verification

    L700462 hydrochloride monohydrate; MK383 hydrochloride monohydrate

    		 Integrin Cardiovascular Disease
    Tirofiban (L700462) hydrochloride monohydrate is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban hydrochloride monohydrate induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban hydrochloride monohydrate can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area .
    Tirofiban hydrochloride monohydrate
  • HY-106262
    Delcasertib

    KAI-9803; BMS-875944

    		 PKC Cardiovascular Disease Inflammation/Immunology
    Delcasertib (KAI-9803) is a potent and selective δ-protein kinase C (δPKC) inhibitor. Delcasertib (KAI-9803) could ameliorate injury associated with ischemia and reperfusion in animal models of acute myocardial infarction (MI) .
    Delcasertib
  • HY-117627
    L 158338

    		Angiotensin Receptor Cardiovascular Disease
    L 158338 is an angiotensin II receptor antagonist. L 158338 alleviates acidosis and increases coronary blood flow during the ischemic period and increases coronary blood flow during the reperfusion period. L 158338 can be used to study myocardial injury during ischemia and reperfusion .
    L 158338
  • HY-17369R
    Tirofiban hydrochloride monohydrate (Standard)

    L700462 hydrochloride monohydrate (Standard); MK383 hydrochloride monohydrate (Standard)

    		 Reference Standards Integrin Cardiovascular Disease
    Tirofiban (hydrochloride monohydrate) (Standard) is the analytical standard of Tirofiban (hydrochloride monohydrate). This product is intended for research and analytical applications. Tirofiban (L700462) hydrochloride monohydrate is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban hydrochloride monohydrate induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban hydrochloride monohydrate can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area .
    Tirofiban hydrochloride monohydrate (Standard)
  • HY-17369BR
    Tirofiban (Standard)

    L700462 (Standard); MK383 (Standard)

    		 Reference Standards Integrin Cardiovascular Disease
    Tirofiban (Standard) is the analytical standard of Tirofiban. This product is intended for research and analytical applications. Tirofiban (L700462) is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area .
    Tirofiban (Standard)
  • HY-149586
    ROS-IN-2

    		Reactive Oxygen Species (ROS) Others
    ROS-IN-2 (compound 85) is a seco-lupane triterpenoid derivative. ROS-IN-2 blocks ROS production and protects mitochondria from damage by inhibiting excessive production of oxidative stressors. ROS-IN-2 can be used for myocardial ischemia/reperfusion (MI/R) injury research .
    ROS-IN-2
  • HY-172959
    mPTP-IN-1

    		Mitochondrial Metabolism Cardiovascular Disease
    mPTP-IN-1 (Compound 14e) is a mitochondrial permeability transition pore (mPTP) inhibitor. mPTP-IN-1 blocks calcium-induced mPTP opening by targeting the C subunit of ATP synthase. mPTP-IN-1 can be used to study myocardial ischemia/reperfusion injury (IRI) .
    mPTP-IN-1
  • HY-145237
    BM213
    2 Publications Verification

    		 Complement System Apoptosis Reactive Oxygen Species (ROS) Cancer
    BM213 is a selective C5aR agonist, with an EC50 of 59 nM. BM213 specifically activates the C5a-C5aR1 axis, which in turn promotes neutrophil extracellular trap (NET) formation and exacerbates inflammatory responses. BM213 significantly induces ventricular dilationin, promotes myocardial ROS production, and induces cardiomyocyte apoptosis in rats. BM213 can be used for the study of myocardial ischemia/reperfusion (I/R) injury .
    BM213
  • HY-172342
    MitoA bromide

    		Fluorescent Dye Cardiovascular Disease
    MitoA (bromide) is a mitochondria-targeted H2S probe, which can be used to assess relative changes in mitochondrial levels of H2S in vivo. MitoA (bromide) can accumulate inside mitochondria within tissues in vivo due to tryphenylphosphonium (TPP) cation. MitoA (bromide) can be studied in research on myocardial ischemia .
    MitoA bromide
  • HY-130272
    Anti-MI/R injury agent 1

    		Others Cardiovascular Disease
    Anti-MI/R injury agent 1 (compound 18), a Panaxatriol derivative, is an orally active, potent anti-myocardial ischemia/reperfusion (anti-MI/R) injury agent. Anti-MI/R injury agent 1 enhances oxygen-glucose deprivation and reperfusion (OGD/R)-induced cardiomyocyte injury cell viability. Anti-MI/R injury agent 1 can markedly reduce myocardial infarction size, decrease circulating cardiac troponin I (cTnI) leakage, and alleviate cardiac tissue damage in the rats .
    Anti-MI/R injury agent 1
  • HY-A0113
    Cilazaprilat

    Ro 31-3113

    		 Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Cilazaprilat is an inhibitor of angiotensin-converting enzyme (ACE; IC50=0.7 nM for the rat enzyme) and an active metabolite of Cilazapril (HY-A0043). It decreases creatine kinase release in primary neonatal rat cardiac myocytes in an in vitro model of ischemia-reperfusion injury induced by hypoxia and reoxygenation when used at a concentration of 10 μM.3 Intra-arterial administration of cilazaprilat (3 μg/kg per minute) increases coronary blood flow and fractional shortening in a dog model of coronary hypoperfusion-induced myocardial ischemia.
    Cilazaprilat
  • HY-W783623
    1,3-Didocosahexaenoyl glycerol

    DG(22:6/0:0/22:6); 1,3-Didocosahexaenoin

    		 Biochemical Assay Reagents Cardiovascular Disease
    1,3-Didocosahexaenoyl glycerol (DG(22:6/0:0/22:6); 1,3-Didocosahexaenoin) is an ω-3 polyunsaturated fatty acid, which exhibits cardioprotective effects in rat myocardial ischemia/reperfusion (I/R) injury model through conjugation with Poly-l-glutamic acid (PGA) .
    1,3-Didocosahexaenoyl glycerol
  • HY-103445
    SSR69071

    		Elastase Cardiovascular Disease
    SSR69071 is a potent, orally active and selective inhibitor of neutrophil elastase. SSR69071 reduces myocardial infarct size following ischemia-reperfusion injury . SSR69071 displays a higher affinity for human elastase (Ki=0.0168 nM) than for rat (Ki=3 nM), mouse (Ki=1.8 nM), and rabbit (Ki= 58 nM) elastases .
    SSR69071

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: